SALARIUS PHARMACEUTICALS INC (SLRX)
US79400X4043 - Common Stock
Which stocks are moving on Tuesday?
Top movers analysis one hour before the close of the markets on 2025-01-14: top gainers and losers in today's session.
What's going on in today's session
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement
Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI)...
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q2 2024
SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with!
Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?
While Salarius Pharmaceuticals encountered a hiccup in its genomics research, the possibility of new funding may have lifted SLRX stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are a hot topic on Friday as we check out all of the stories affecting shares on the last day of trading this week!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news affecting shares this morning!
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported...
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein...
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024
SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salarius Pharmaceuticals (NASDAQ:SLRX) just reported results for the first quar...
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting off the day with a breakdown of the biggest pre-market stock movers that traders need to know about on Monday morning.
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023
SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salarius Pharmaceuticals (NASDAQ:SLRX) just reported results for the fourth qua...
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic...
Salarius's CEO David Arthur steps down (NASDAQ:SLRX)
Salarius Pharmaceuticals announces cost-savings measures including CEO transition, reduced expenses, and compensation, to support ongoing clinical trials.